Objective, computerized video-based rating of blepharospasm severity

ABSTRACT

Objective: To compare clinical rating scales of blepharospasm severity with involuntary eye closures measured automatically from patient videos with contemporary facial expression software.

Methods: We evaluated video recordings of a standardized clinical examination from 50 patients with blepharospasm in the Dystonia Coalition’s Natural History and Biorepository study. Eye closures were measured on a frame-by-frame basis with software known as the Computer Expression Recognition Toolbox (CERT). The proportion of eye closure time was compared with 3 commonly used clinical rating scales: the Burke-Fahn-Marsden Dystonia Rating Scale, Global Dystonia Rating Scale, and Jankovic Rating Scale.

Results: CERT was reliably able to find the face, and its eye closure measure was correlated with all of the clinical severity ratings (Spearman $\rho = 0.56$, 0.52, and 0.56 for the Burke-Fahn-Marsden Dystonia Rating Scale, Global Dystonia Rating Scale, and Jankovic Rating Scale, respectively, all $p < 0.0001$).

Conclusions: The results demonstrate that CERT has convergent validity with conventional clinical rating scales and can be used with video recordings to measure blepharospasm symptom severity automatically and objectively. Unlike EMG and kinematics, CERT requires only conventional video recordings and can therefore be more easily adopted for use in the clinic.

Neurology® 2016;87:1–8

GLOSSARY

BFM = Burke-Fahn-Marsden Dystonia Rating Scale; CERT = Computer Expression Recognition Toolbox; CI = confidence interval; GDRS = Global Dystonia Rating Scale; ICC = intraclass correlation; JRS = Jankovic Rating Scale; UCSD = University of California, San Diego; WUSM = Washington University School of Medicine.

Blepharospasm is characterized by loss of voluntary control over orbicularis oculi muscles, causing involuntary eyelid closure. It is one of the most common forms of isolated dystonia and can cause functional blindness, significant social disability, and decreased quality of life. Periodic botulinum neurotoxin injections provide some symptomatic relief, but the development of more effective therapies requires sensitive and objective methods to rate symptom severity.

Current rating scales such as the Burke-Fahn-Marsden Dystonia Rating Scale (BFM), the Global Dystonia Rating Scale (GDRS), the Jankovic Rating Scale (JRS), and the recently developed rating scale for blepharospasm are based on inherently subjective clinician evaluation. This raises concerns about interrater reliability and necessitates a substantial effort to evaluate the reliability of such rating scales. In contrast, common availability of inexpensive digital video cameras enables objective video recording analysis with a rapidly growing suite of contemporary artificial intelligence software. One such implementation is the Computer Expression Recognition Toolbox (CERT). CERT combines algorithms from computer

From the Computational Neurobiology Laboratory (D.A.P., T.J.S.) and Howard Hughes Medical Institute (T.J.S.), Salk Institute for Biological Studies; Institute for Neural Computation (D.A.P., G.C.L., M.S.B., T.J.S.), Kavli Institute for Brain and Mind (D.A.P., T.J.S.); Machine Perception Laboratory (G.C.L., M.S.B.), and Division of Biological Sciences (T.J.S.), University of California, San Diego, La Jolla; Sobell Department of Motor Neuroscience and Movement Disorders (A.M.), National Hospital of Neurology and Neurosurgery, Institute of Neurology, University College London, UK; Departments of Neurology, Radiology, and Anatomy and Neurobiology, and Programs in Physical Therapy and Occupational Therapy (J.S.P.), Washington University School of Medicine, St. Louis, MO; Departments of Neurology, Human Genetics, and Pediatrics (H.A.J.), Emory University, Atlanta, GA; and Human Motor Control Section (M.H.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
vision and machine learning. It automatically finds the face and detects facial “action units” on the basis of the facial action coding system,\textsuperscript{14} widely used for coding facial expressions in behavioral sciences.\textsuperscript{15} In neurologically normal individuals, CERT\textsuperscript{16} demonstrates state-of-the-art performance, discriminating emotions in benchmark datasets\textsuperscript{16} consisting of >100 individuals producing >500 sequences of expressions.\textsuperscript{11,17}

We evaluated the clinical utility of CERT for measuring blepharospasm severity through 2 objectives: to test convergent validity, i.e., whether CERT measures of involuntary eye closure agree with clinical severity ratings, and to determine the viability of CERT, i.e., the proportion of video frames on which CERT can automatically find the patient’s face.

**METHODS Patients.** We evaluated patients previously recruited into the Dystonia Coalition’s multicenter Natural History and Biorepository of Isolated Dystonia cross-sectional study. The biorepository includes a centralized, web-based platform for securely uploading, storing, and serving patient data, including video recordings.\textsuperscript{18} The system meets Health Insurance Portability and Accountability Act guidelines for security and has been approved by the Human Research Protection Office at the Washington University School of Medicine (WUSM). The Human Research Protection Office at the University of California, San Diego (UCSD) also approved access to the patient data by the UCSD team, including the ability to observe streamed videos (protocol 111255X). We identified 50 patients with isolated dystonia, including at least blepharospasm with or without lower facial involvement, for subsequent analysis with CERT. Most patients were treated with botulinum toxin, with the last injection at least 2 months before the examination. Our only inclusion criterion was that the GDRS and BFM clinical severity ratings were conducted at the same visit as the video recording (for patient characteristics, see the table).

**Clinical examination and severity ratings.** Patients underwent a standardized clinical examination based in part on a protocol developed by the Dystonia Study Group,\textsuperscript{7} modified to accommodate features of many types of dystonia as described by Yan et al.,\textsuperscript{18} and recorded with digital video at 30 frames per second. We extracted from the videos the part of the examination protocol focusing on blepharospasm (part I, steps 1–4).\textsuperscript{18} The participant is seated in a chair facing the video camera. Feet are resting on the floor, and hands are resting in the lap. The camera is zoomed in to capture the head and shoulders only: (1) at rest, eyes open for 10 seconds; (2) at rest, eyes closed gently for 10 seconds; (3) at rest, after eyes are opened, for another 10 seconds; and (4) forced eyelid closure 3 times, with the effect observed for 5 seconds after each closure.

One patient was excluded from further analysis because she was not observed on video to not fully close her eyes during periods of instructed eye closure.

Patient videos were accompanied by clinical severity scores. In this study, we specifically focused on blepharospasm severity ratings and did not include “duration” factors because of the relatively short observation periods. Site ratings, normally conducted live by clinicians who were familiar with the patient’s history, included the upper face item from the BFM\textsuperscript{5-6} and GDRS.\textsuperscript{7} Three movement disorders experts (M.H., H.J., J.P.), blinded to the live ratings, scored the videos using the BFM, GDRS, and JRS.\textsuperscript{8} Interrater agreement was evaluated with the intraclass correlation (ICC), and then the 3 raters’ video scores were averaged on each patient for each rating scale.

**Computational video analysis with CERT.** To mitigate security risks associated with transferring files containing video recordings of patient faces, we developed an iterative video processing procedure between the Dystonia Coalition Biorepository team at WUSM and the primary analysis team at UCSD. First, at WUSM, video files were cropped to include just the relevant part of the recording and saved as a separate file that was also re-encoded for streaming. Second, the UCSD team reviewed the streamed videos to validate proper cropping. Third, the WUSM team manually segmented the videos into 9 periods of the examination protocol, 5 periods when the eyes should be open and 4 periods of instructed eye closures, using open-source video annotation software (Elan,\textsuperscript{19} Max Planck Institute for Psycholinguistics, The Language Archive, Nijmegen, the Netherlands), saving as outputs the time stamps of each segment boundary. The WUSM team also ran the video file through CERT. Both the segment boundary time stamps and CERT outputs, without video or patient-identifying information, were sent to the UCSD team as ASCII files. Fourth, the UCSD team reviewed the Elan output files against the streamed videos to validate the segmenting process.

In this study, we used CERT version 4.4.5, previously available from UCSD for academic use and now available as FACET commercial software from iMotions.com (see the CERT processing pipeline depicted in figure 1). Faces were automatically located in each video frame by searching for standard facial landmarks such as eyes, nose, and mouth using previously published computer vision methods.\textsuperscript{17,19} We set an a priori criterion of 80% to be the minimum proportion of face-found frames for reasonable assessment of the patient’s eye closure features. The raw output of CERT consisted of a continuous-valued measure of eye closure for each video frame. Because of the nature of the machine learning classifier from which it was derived, it was dimensionless and relative, with more negative values associated with open eyes and more positive with closed eyes. Downstream analysis with the CERT raw measure of eye closure included only the face-found frames and was conducted with MATLAB (The

<table>
<thead>
<tr>
<th>Table Patient characteristics (n = 49)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
</tr>
<tr>
<td>Onset age, y</td>
</tr>
<tr>
<td>Sex, F/M</td>
</tr>
<tr>
<td>Disease duration, y</td>
</tr>
<tr>
<td><strong>Severity ratings</strong></td>
</tr>
<tr>
<td>BFM (live)</td>
</tr>
<tr>
<td>GDRS (live)</td>
</tr>
<tr>
<td>BFM (video)</td>
</tr>
<tr>
<td>GDRS (video)</td>
</tr>
<tr>
<td>JRS (video)</td>
</tr>
</tbody>
</table>

BFM = Burke-Fahn-Marsden Dystonia Rating Scale; GDRS = Global Dystonia Rating Scale; JRS = Jankovic Rating Scale.

Values expressed as mean ± SD (range).
To determine the percentage of time of eyes closed during the periods of instructed eye opening, we needed a way to declare eyes open or closed on each video frame, so we calculated an eye closure threshold for each patient. The video examination protocol included substantial periods of instructed eye closures and eye openings. For this protocol, the distributions of the CERT raw eye closure measure over time would be bimodal for neurologically normal individuals, in which case choosing a threshold between eyes open and eyes closed states would be trivial. In contrast, we hypothesized that the distribution would not be bimodal for patients with blepharospasm, so we first evaluated the distributions for bimodality using the Sarle bimodality test (see appendix e-1 at Neurology.org). In the event that 10% of the patients’ eye closure distributions were not bimodal, we used a more conventional thresholding method, similar to that used by Bologna et al. Specifically, we calculated the mean of the means of the lowest 5% and highest 5% of samples. Using this per-patient eye closure threshold, we calculated the percentage of time that each patient’s eyes were closed when the patient was instructed to have them open, i.e., the number of video frames on which eyes are closed divided by the total number of video frames from the concatenated eyes open time segments.

**Statistical analysis.** Correlations were evaluated with the Spearman rank correlation coefficient ($\rho$) with JMP (SAS Institute Inc, Cary, NC) and characterized with the Cohen effect size conventions. One-sided correlation comparisons were made with Fisher $z$ transforms of the Spearman $\rho$ values, parameterized for dependent and overlapping groups (cocor, http://comparingcorrelations.org). We used an $\alpha$ level of 0.05 to determine significance and 95% confidence intervals (CIs).

**RESULTS Clinical ratings.** The demographics of our patient cohort (table) were consistent with blepharospasm epidemiology. Although their severity was, on average, relatively mild (mean BFM $= 2.2$ for both live and video ratings and GDRS $= 3.8$ and 3.7 for live and video ratings, respectively), individual patient severity ratings covered the full range of the severity rating scales. Reliability among the 3 video raters was assessed with the ICC, class 2, because all raters rated all participants (Real Statistics Resource Pack software, release 4.5, copyright 2013–2016, Charles Zaiontz, www.real-statistics.com). There was moderate agreement among the video raters on all 3 rating scales, consistent with prior studies using these scales. Specifically, the ICCs (lower–upper CIs) were 0.58 (0.42–0.71) for the BFM, 0.62 (0.44–0.75) for the GDRS, and 0.57 (0.39–0.72) for the JRS. The live and video-based ratings were in general agreement (figure 2) for both the BFM [$\text{Spearman } \rho(47) = 0.61, \ p < 0.0001$] and the GDRS [$\text{Spearman } \rho(47) = 0.58, \ p < 0.0001$].

**CERT viability and convergent validity with clinical scales.** CERT was able to find the face in 100% of the video frames for 46 patients and in 95%, 94%, and 93% for the other 3 patients. Patients exhibited a wide variety of bimodality in the distributions of the CERT raw eye closure measure over all of the
video frames (figure 3). Some exhibited clearly bimodal distributions (figure 3A), while others did not (figure 3B). On the basis of the Sarle bimodality test (see appendix e-1), a substantial portion (12 of 49, 24%) had distributions that were not bimodal (figure 3C). Thus, we used the conventional method for thresholding the eye closure output (see Methods). This per-patient threshold was then used to determine whether the eyes were closed on each video frame and the percentage of frames during the instructed “eyes open” segments used to calculate each patient’s CERT-based metric: eye closure time (percent). The total duration of the concatenated eyes open segments was 43 ± 8 seconds (range 28–64 seconds). The CERT eye closure time (percent) was correlated with all of the clinical rating scales (figure 4), both for the live [BFM: Spearman $r(47) = 0.46$, $p = 0.0008$; GDRS: Spearman $r(47) = 0.30$, $p = 0.035$] and for the video-based severity [BFM: Spearman $r(47) = 0.56$, $p < 0.0001$; GDRS: Spearman $r(47) = 0.52$, $p < 0.0001$; JRS: Spearman $r(47) = 0.56$, $p < 0.0001$] ratings.

The correlations between the CERT eye closure time (percent) and the severity ratings were higher for the video-based than for the live severity ratings. This difference ($0.56 > 0.46$) was not significant for the BFM (based on Pearson and Filon $z = 0.953$, $p = 0.170$ and Meng et al $z = 0.926$, $p = 0.177$; difference CI = $-0.151$ to 0.422). The difference ($0.52 > 0.30$) was, however, significant for the GDRS (Pearson and Filon $z = 1.887$, $p = 0.030$ and Meng et al $z = 1.830$, $p = 0.034$), although the difference CI ($-0.019$ to $0.553$) is not consistent with an effect.

**DISCUSSION** We analyzed the CERT eye closure measures to objectively compute the percent of time that the patients’ eyes were closed when the patients were instructed to open them. We found correlations between this measure and all of the clinical severity measures. Thus, the CERT eye closure measure exhibits convergent validity with conventional clinician-scored rating scales. This overarching result held across all 3 clinical rating scales used (the BFM, GDRS, and JRS), as well as the 2 modalities in which they were administered (live and from video observations).

The correlations between CERT and the clinical severity ratings varied slightly, depending on whether the ratings were live or based on video review. This is expected, given the moderate but imperfect correlation between the live and video-based rating modalities, bimodality measure). Horizontal line represents threshold above which distribution is conventionally considered bimodal (Sarle b, see appendix e-1). BFM = Burke-Fahn-Marsden Dystonia Rating Scale; GDRS = Global Dystonia Rating Scale; JRS = Jankovic Rating Scale. AU = arbitrary units.
a discrepancy that has been widely acknowledged but not systematically investigated. There was a trend toward the CERT eye closure measure correlating better with video than live ratings, reaching significance for some but not all statistical comparisons. CERT and the video raters may detect eye closures that are missed by a live rater who may not direct complete attention to observing the patient when simultaneously recording scores. Perhaps it is more important that the video raters evaluate the same video that CERT analyzed, which may enhance convergence.

CERT was robust with respect to variable head movement and variable lighting conditions during the video recording, reliably registering the face an average of 99.6% of the video frames across all patients. The lowest percentage of face-found frames, at 93%, far exceeded our a priori threshold of 80% for retaining videos for further analysis. This is particularly encouraging for the relevance of CERT for patients with cranial dystonia with or without comorbid cervical dystonia because about one-fourth of the patients in this study also had head tremor. It also supports the broader applicability of CERT for analyzing video recordings from a conventional clinical setting because no special efforts were made to optimize lighting conditions in the present study.

The present study has a few noteworthy limitations. First, severity is not uniformly distributed. In the case of the GDRS, for example, the preponderance of patients were rated 3 to 4, with relatively few rated in the 1 to 2 and 8 to 10 ranges. Although this likely represents the larger population of patients diagnosed with blepharospasm, it diminishes our ability to test convergent validity among rating methods at the low and high extremes of severity. Post hoc review of the 2 notable outliers, patients with 80% and 78% eye closure, suggests that these were legitimate measures of severe blepharospasm and not CERT processing artifacts. This emphasizes limitations in the linearity of the clinical rating scales at the high end. Second, the present study included 49 patients. A larger cohort may increase statistical power and include more severe patients, depending on the distribution in the population and any sampling bias. Third, the video observation period may be too brief, potentially providing insufficient duration of instructed eyes open periods to permit detection of low but still pathologic amounts of eye closure. The floor effect apparent in the distributions of the CERT eye closure measure (see figure 4), in which several patients exhibited little if any eye closure during the instructed eyes open periods, supports this possibility. In this study, the cumulative duration of instructed eyes open periods averaged 43 seconds, whereas other studies used 120 seconds of video to evaluate blink rate in blepharospasm. Nevertheless,
Using <2 minutes of video recorded during a standard clinical examination, we have demonstrated that CERT can objectively measure eye closure in blepharospasm. No separate technology or procedure is required during the examination, and the video can be analyzed offline. Thus, a CERT-based objective measure can supplement traditional subjective ratings of blepharospasm severity with minimal additional burden in the clinical setting.

**AUTHOR CONTRIBUTIONS**


**ACKNOWLEDGMENT**

The authors thank the WUSM Biorepository team, including Christina Zukas for help preprocessing the video recordings, Ling Yan and Laura Wright for organizing patient clinical data, and Matt Hicks for technical support. The authors also thank Giovanni Defazio, University of Bari, and Davide Martino, King’s College London, for assistance and data used in pilot testing parts of the CERT methodology, as well as Mark Appelbaum, UCSD, for suggestions on statistical analysis.

**STUDY FUNDING**

This study was funded by the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). Dr. Hallett is supported by the National Institute of Neurologic Disorders and Stroke Intramural Program. None of the sponsors were involved in study design, collection, analysis, and interpretation of data; writing the report; or decision to submit the article for publication.

**DISCLOSURE**

D. Peterson serves on the Scientific Advisory Board for the Tourette Association of America, currently receives grant support from the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center, SMA-1041759), was a consultant for Brain Corporation, and has previously received grant support from the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). G. Littlewort was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

1. Bartlett, Littlewort-Ford, Movellan, Fasel, Frank. Automated facial action coding system. US Patent 700086215 A1 (2014). M. Bartlett was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

2. Apps in pilot testing parts of the CERT methodology, as well as Mark Appelbaum, UCSD, for suggestions on statistical analysis.

**STUDY FUNDING**

This study was funded by the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). Dr. Hallett is supported by the National Institute of Neurologic Disorders and Stroke Intramural Program. None of the sponsors were involved in study design, collection, analysis, and interpretation of data; writing the report; or decision to submit the article for publication.

**DISCLOSURE**

D. Peterson serves on the Scientific Advisory Board for the Tourette Association of America, currently receives grant support from the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center, SMA-1041759), was a consultant for Brain Corporation, and has previously received grant support from the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). G. Littlewort was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

1. Bartlett, Littlewort-Ford, Movellan, Fasel, Frank. Automated facial action coding system. US Patent 700086215 A1 (2014). M. Bartlett was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

2. Apps in pilot testing parts of the CERT methodology, as well as Mark Appelbaum, UCSD, for suggestions on statistical analysis.

**STUDY FUNDING**

This study was funded by the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). Dr. Hallett is supported by the National Institute of Neurologic Disorders and Stroke Intramural Program. None of the sponsors were involved in study design, collection, analysis, and interpretation of data; writing the report; or decision to submit the article for publication.

**DISCLOSURE**

D. Peterson serves on the Scientific Advisory Board for the Tourette Association of America, currently receives grant support from the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center, SMA-1041759), was a consultant for Brain Corporation, and has previously received grant support from the Dystonia Coalition (NS065701 and TR001456) from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and the National Institute of Neurologic Disorders and Stroke, the Bachmann-Strauss Dystonia & Parkinson Foundation, the Benign Essential Blepharospasm Research Foundation, the Kavli Institute for Brain and Mind at UCSD, the National Institute of Mental Health (NIMH ST32-MH020002), and the National Science Foundation (the Temporal Dynamics of Learning Center, a Science of Learning Center [SMA-1041759] and the program in Mind, Machines, Motor Control [EFRI-1137279]). G. Littlewort was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

1. Bartlett, Littlewort-Ford, Movellan, Fasel, Frank. Automated facial action coding system. US Patent 700086215 A1 (2014). M. Bartlett was cofounder, employee, and shareholder of Emotient, Inc from 2010 to 2016. Emotient created and marketed scientific software for expression measurement from video. She has also received royalties on the following patents

2. Apps in pilot testing parts of the CERT methodology, as well as Mark Appelbaum, UCSD, for suggestions on statistical analysis.
F. Parent owns UCSD: Bartlett, Littlewort-Ford, Movellan, Fasel, Frank. Automated facial action coding system. US Patent 20100086215 A1 (2014). A. Macerollo reports no disclosures relevant to the manuscript. J. Perlmutter serves on the Editorial Board of Neurology, receives research support from NIH grants RO1NS41599, RO1NS075321, R01NS058714, NS075527, U10NS07384, R01NS077946, RO1NS077959, RO1NS090214, NCATS U54TR001456, ES021488, and RO1AG050263; the American Parkinson Disease Association (APDA), the Greater St. Louis Chapter of the APDA, the Huntington Disease Society of America, CHDI, the Barnes Jewish Hospital Foundation, the Fixel Foundation, and the Oertli Foundation. He has received consulting fees for medical-legal consultations. He also serves unpaid on the Scientific Advisory Board for the Dystonia Medical Research Foundation, the APDA, and the Greater St. Louis Chapter of the APDA. He serves unpaid as the chair of the Standards Committee for the Huntington Disease Study Group, cochair of the Scientific Review Committee of the Parkinson Study Group, a member of the Peripheral and Central Nervous System Drugs Advisory Committee of the US Food and Drug Administration, and a member of the American College of Radiology Panel on Appropriateness Criteria–Neuroradiology. H. Jinnah has active grant support from the NIH, Merz Inc, Ipsen Inc, the Benign Essential Blepharospasm Research Foundation, and Cure Dystonia Now. He also is principal investigator for the Dystonia Coalition, which receives the majority of its support through NIH grant TR001456 from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences and NS065701 from the National Institutes of Neurologic Disorders and Stroke. The Dystonia Coalition receives additional material or administrative support from industry sponsors (Allergan Inc and Merz Pharmaceuticals) and private foundations (the American Dystonia Society, Beat Dystonia, the Benign Essential Blepharospasm Foundation, Cure Dystonia Now, Dystonia Inc, Dystonia Ireland, the Dystonia Medical Research Foundation, the European Dystonia Federation, the Foundation for Dystonia Research, the National Spasmodyc Dysphonia Association, and the National Spasmodic Torticolli Association). Dr. Jinnah recently served as a consultant for Pyasdon Pharmaceuticals and Medtronic, Inc. He also serves on the Scientific Advisory Board for Cure Dystonia Now, the Dystonia Medical Research Foundation, Lesch-Nyhan Action France, the Lesch-Nyhan Syndrome Children’s Research Foundation, and Tyler’s Hope for a Cure. M. Hallett is involved in the development of Neuroglyphics for tremor assessment and has a collaboration with Portland State University to develop sensors to measure tremor. He serves as chair of the Medical Advisory Board for and may receive honoraria and funding for travel from the Neurotoxin Institute. He may accrue revenue on US Patent 6,780,413 B2: Immunostimulant (MAB-Ricin) for the treatment of focal movement disorders (issued August 24, 2004), and US Patent 7,407,478: Coil for magnetic stimulation and methods for using the same (H-coil) (issued August 5, 2008); in relation to the latter, he has received license fee payments from the NIH (from Brainwave) for licensing of this patent. He is on the Editorial Board of 20 journals and received royalties and/or honoraria from publishing from Cambridge University Press, Oxford University Press, John Wiley & Sons, Wolters Kluwer, Springer, and Elsevier. He has received honoraria for lecturing from Columbia University. Dr. Hallett’s research at the NIH is largely supported by the NIH Intramural Program. Supplemental research funds have been granted by BGN Peptides, S.A. for treatment studies of blepharospasm, Medronic, Inc, for studies of deep brain stimulation, Parkinson Alliance for studies of eye movements in Parkinson disease, UniQure for a clinical trial of AA-V2-GDNF for Parkinson disease, Merz for treatment studies of focal hand dystonia, and Allergan for studies of methods to inject botulinum toxins. T. Sejnowski serves on the BRAIN Initiative Working Group to the NIH director, currently receives grant support from the Howard Hughes Medical Institute and the NIH (R01-EB009282, P41 GM03712, R01 MH094670), and has previously received grant support from the NIH (R01 EB009282, P01 HD033113, R01 DA030749, R01 GM086883, R01 MH079076, R01 NS059740) and the National Science Foundation (SMA-1344471, PHY-0822283). Go to Neurology.org for full disclosures.

Received May 2, 2016. Accepted in final form August 2, 2016.

REFERENCES

**Objective, computerized video-based rating of blepharospasm severity**

David A. Peterson, Gwen C. Littlewort, Marian S. Bartlett, et al.

*Neurology* published online October 21, 2016

DOI 10.1212/WNL.0000000000003336

This information is current as of October 21, 2016

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://www.neurology.org/content/early/2016/10/21/WNL.0000000000003336.full.html">http://www.neurology.org/content/early/2016/10/21/WNL.0000000000003336.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://www.neurology.org/content/suppl/2016/10/21/WNL.0000000000003336.DC1.html">http://www.neurology.org/content/suppl/2016/10/21/WNL.0000000000003336.DC1.html</a></td>
</tr>
</tbody>
</table>
| Subspecialty Collections      | This article, along with others on similar topics, appears in the following collection(s): 
Blepharospasm [http://www.neurology.org/cgi/collection/blepharospasm](http://www.neurology.org/cgi/collection/blepharospasm)
Dystonia [http://www.neurology.org/cgi/collection/dystonia](http://www.neurology.org/cgi/collection/dystonia) |
| Permissions & Licensing       | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: [http://www.neurology.org/misc/about.xhtml#permissions](http://www.neurology.org/misc/about.xhtml#permissions) |
| Reprints                      | Information about ordering reprints can be found online: [http://www.neurology.org/misc/addir.xhtml#reprintsus](http://www.neurology.org/misc/addir.xhtml#reprintsus) |